Although a placebo-controlled, repeat-cycle, follow-up trial demonstrated significant clinical activity in RA, unacceptable CD4 lymphopenia, and skin rashes lead to discontinuation of therapy (66). The gene discussed is CD4; the disease is rheumatoid arthritis.